|Bid||65.65 x 800|
|Ask||65.99 x 1100|
|Day's Range||66.60 - 69.20|
|52 Week Range||19.51 - 73.72|
|Beta (5Y Monthly)||1.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 03, 2021 - Feb 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.18|
ARWR earnings call for the period ending September 30, 2020.
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) decreased 2.49% in after-market trading after the company reported Q4 results.Quarterly Results Earnings per share decreased 536.36% over the past year to ($0.48), which missed the estimate of $0.12.Revenue of $7,632,000 decreased by 82.37% from the same period last year, which missed the estimate of $49,240,000.Guidance Earnings guidance hasn't been issued by the company for now.Arrowhead Pharmaceuticals hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Nov 23, 2020View more earnings on ARWRTime: 04:30 PMET Webcast URL: https://edge.media-server.com/mmc/p/xqpf829iTechnicals Company's 52-week high was at $73.7252-week low: $19.51Price action over last quarter: Up 63.33%Company Profile Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Monday's After-Market Session * Earnings Scheduled For November 23, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Arrowhead announced financial results for its fiscal year ended September 30, 2020